Skip to content
10-Q

Quarterly Report

Zevra Therapeutics, Inc. ZVRA

0001434647-26-000031

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 59.12M sh
Shares Diluted Q1 2026 · Mar 31, 2026 60.23M sh
Shares Diluted Q1 2026 · Mar 31, 2025 54.1M sh
Capex Q1 2026 · Mar 31, 2026 $35K
Capex Q1 2026 · Mar 31, 2025 $99K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $6.14M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.22M
Long Term Debt Q1 2026 · Mar 31, 2026 $0
Long Term Debt Q1 2026 · Dec 31, 2025 $61.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $95.6M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $62.41M
Stockholders Equity Q1 2026 · Mar 31, 2026 $205.8M
Stockholders Equity Q1 2026 · Dec 31, 2025 $154.66M
Stockholders Equity Q1 2026 · Mar 31, 2025 $41.02M
Stockholders Equity Q1 2026 · Dec 31, 2024 $39.67M
Current Liabilities Q1 2026 · Mar 31, 2026 $47.03M
Current Liabilities Q1 2026 · Dec 31, 2025 $39.28M
Total Liabilities Q1 2026 · Mar 31, 2026 $72.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $130.07M
Current Assets Q1 2026 · Mar 31, 2026 $229.97M
Current Assets Q1 2026 · Dec 31, 2025 $223.01M
Total Assets Q1 2026 · Mar 31, 2026 $278.58M
Total Assets Q1 2026 · Dec 31, 2025 $284.73M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.60
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.06
Eps Basic Q1 2026 · Mar 31, 2026 $0.62
Eps Basic Q1 2026 · Mar 31, 2025 −$0.06
Sga Expense Q1 2026 · Mar 31, 2026 $20.78M
Sga Expense Q1 2026 · Mar 31, 2025 $19.55M
Net Income Q1 2026 · Mar 31, 2026 $37.89M
Net Income Q1 2026 · Mar 31, 2025 −$3.1M
Operating Income Q1 2026 · Mar 31, 2026 $52.15M
Operating Income Q1 2026 · Mar 31, 2025 −$5.36M